Universal amplifier system for high-fidelity multi-modal biosignal recordings

描述（由申请人提供）：生物电信号的测量、监测和使用已经从心脏电活动的测量发展到包括心脏、骨骼和平滑肌、大脑和周围神经组织等组织。与此同时，捕捉和解释这些微小信号的专用设备也在不断发展。然而，生物电信号测量的未来正朝着多源、多地点的测量和集成方向发展，这就导致了需要通过为特定信号设计的专用设备来集成信号和源的问题。为了克服这个问题，在对测量和采集问题进行重新分析之后，印第安纳大学普渡大学（IUPUI）的Refer2Input （R2i）及其研究合作伙伴设计了一种新型生物电compander系统。由此产生的通用可逆放大器系统发挥了模拟和数字世界的优势，跨越了所有生物电信号的范围，并且能够在没有硬件重新配置的情况下重新聚焦到特定信号。在这个STTR中，R2i及其在IUPUI的研究伙伴将进一步开发这项技术并证明其可行性。第一阶段的具体目标是：1)开发和实施硬件平台；2)开发和实施软件平台；3)完成硬件和软件系统的体内验证。经过验证和测试的UIA系统将成为第二阶段开发多模态、多频率应用的基础仪器。该系统充分利用了UIA系统的硬件通用性和实时重聚焦能力，具有相当大的商业市场。该系统将简化研究和临床实验室的仪器需求，通过融合到一个单一的公共记录平台来降低成本。

DESCRIPTION (provided by applicant): The measurement, monitoring and use of bioelectric signals has evolved from the measurement of the electrical activity of the heart to encompass tissues ranging from cardiac, skeletal and smooth muscles, to brain and peripheral nerve tissues. Together with this development has been the evolution of specialized equipment to capture and interpret these minute signals. However, the future of bioelectric signals measurement is moving towards the measurement and integration of multiple sources, and multiple locations, which leads to the problem of the need to integrate signals and sources through specialized equipment designed for specific signals. To overcome this problem, Refer2Input (R2i) and its research partners at Indiana University Purdue University (IUPUI) designed novel bioelectric compander system following a reanalysis of the measurement and acquisition problem. The resulting Universal Invertible Amplifier system plays to the strengths of the analog and digital world to span the range of all bioelectric signals coupled with the ability o refocus to specific signals without hardware reconfiguration. In this STTR, R2i and its research partner at IUPUI will further develop this technology and demonstrate feasibility. Phase I Specific Aims are: 1) Develop and implement the hardware platform 2) Develop and implement the software platform and, 3) Complete in- vivo validation of the hardware and software system. The validated and tested UIA system will form the foundational instrumentation basis upon which a multi-modal, multi-frequency applications will be developed in Phase II. This system takes advantage of the universality of the hardware and the real-time refocus abilities of the UIA system, for which a considerable commercial market exists. The system will simplify the instrumentation needs of research and clinical laboratories, reducing costs through convergence to a single common recording platform.